Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 11 EP applications Vinca Raymonde Lardans has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 17, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP11715370

COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR AND AN MTOR INHIBITOR FOR TREATING CANCER

IPC classification:
A61K 31/436, A61K 31/519, A61K 45/06, A61P 35/00
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP11791110

SALT(S) OF 7-CYCLOPENTYL-2 -(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF

IPC classification:
A61K 31/519, A61P 35/00, C07D 401/12
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP12732760

COMBINATION THERAPY

IPC classification:
A61K 31/506, A61K 31/519, A61P 35/00
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis Pharma AG
Status:
PATENT GRANTED
EP12735408

COMBINATION THERAPY COMPRISING A CDK4/6 INHIBITOR AND A PI3K INHIBITOR FOR USE IN THE TREATMENT OF CANCER

IPC classification:
A61K 31/4439, A61K 31/519, A61K 31/535, A61P 35/00
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13772621

COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE

IPC classification:
A61K 31/198, A61K 31/4985, A61K 31/505, A61K 31/519, A61P 35/00, C07D 239/94, C07D 487/04, C07D 491/04
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13802807

COMBINATION THERAPY

IPC classification:
A61K 31/436, A61K 31/519, A61K 45/06, A61P 35/00
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13812167

PHARMACEUTICAL COMBINATION COMPRISING BINIMETINIB

IPC classification:
A61K 31/4184, A61K 31/519, A61P 35/00
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14710654

ORAL FORMULATIONS OF DEFERASIROX

IPC classification:
A61K 9/20, A61K 9/28, A61K 9/50, A61K 31/4196, A61P 39/04
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis AG
Status:
EXAMINATION IN PROGRESS
EP14752433

COMBINATION THERAPY FOR THE TREATMENT OF CANCER

IPC classification:
A61K 31/519, A61K 31/551, A61P 35/00
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14824963

COMBINATION THERAPY COMPRISING AN INHIBITOR OF JAK, CDK AND PIM

IPC classification:
A61K 31/444, A61K 31/519, A61K 45/06, A61P 35/02
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP16188627

ORAL FORMULATIONS OF DEFERASIROX

IPC classification:
A61K 9/20, A61K 9/28, A61K 31/4196, A61P 39/04
Applicant:
Novartis AG
Agent:
Vinca Raymonde Lardans, Novartis Pharma AG
Status:
The patent has been granted

Please Sign in to use this feature